Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | REN | P00797 | 10/20 | 0.35 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.34 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.32 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 2/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.31 |
| ▸ | ADAM9 | Q13443 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3062642 | 0.88 | PDE4B (0.38) | PDE4BCYSLTR2CYSLTR1NPC1RAB9A | |
| SCHEMBL3075362 | 0.88 | CHRNB2 (0.40) | PDE4BCYSLTR2CYSLTR1NPC1RAB9A | |
| SCHEMBL3418125 | 0.83 | REN (0.41) | PDE4BREN | |
| SCHEMBL3079434 | 0.82 | PDE4B (0.34) | PDE4BCYSLTR2CYSLTR1MMP9MMP1 | |
| SCHEMBL3087026 | 0.81 | ALDH1A1 (0.40) | PDE4BNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3079750 | 0.81 | POLB (0.37) | REN | |
| SCHEMBL3074050 | 0.81 | REN (0.40) | PDE4BREN | |
| SCHEMBL3070709 | 0.80 | NAMPT (0.35) | REN | |
| SCHEMBL3084888 | 0.78 | MKNK2 (0.35) | PDE4B | |
| SCHEMBL3061303 | 0.76 | UTS2R (0.41) | PDE4BREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | PDE4B 312/4885REN 1/4885P2RY12 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.